StockData
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. (FDMT) stock analysis

FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 7/302% above fair value
$12.99+0.53 (+4.25%)

Close on Nov 11, 2026Market cap $937.62MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth2Performance2Health3Dividend0

Weak7 of 30 checks passed

4D Molecular Therapeutics passes 7 of the 30 checks behind our score; 15 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
2/6
Financial health
3/6
Dividend
0/6

What stands out

  • Low debt

    Debt is 4.8% of shareholders' equity, under the 40% we consider low.

  • Revenue growing 10%+ a year

    Revenue grew 201% a year over the last three fiscal years.

  • Low bankruptcy risk

    The Altman Z-score is 3.87; above 3 is the safe zone and below 1.8 the distress zone.

  • Growing faster than the industry

    Revenue grew 278712% over the last twelve months; the Drugs median is 8.0%.

What to watch

  • Margin of safety under 20%

    The price is 1.7% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $12.99 is above our fair value estimate of $12.77.

  • Return on equity under 15%

    Return on equity was -43.3% over the last twelve months and averaged -33.6% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -161%, below the 10% that usually covers the cost of capital.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    4D Molecular Therapeutics's price-to-book of 2.30 is above the Drugs median of 2.29.

  • Trading above fair value

    The share price of $12.99 is above our fair value estimate of $12.77.

  • Margin of safety under 20%

    The price is 1.7% above fair value, so there is no margin of safety.

Growth2/6

  • Revenue growing 10%+ a year

    Revenue grew 201% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 278712% over the last twelve months; the Drugs median is 8.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance2/6

  • Return on equity under 15%

    Return on equity was -43.3% over the last twelve months and averaged -33.6% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -161%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    4D Molecular Therapeutics's return on equity of -43.3% is above the Drugs median of -58.8%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -195% over the last twelve months, against a 5-year average of -87852%.

  • Net margin below the industry

    4D Molecular Therapeutics's net margin of -195% is below the Drugs median of -53.0%.

Financial health3/6

  • Low debt

    Debt is 4.8% of shareholders' equity, under the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -797% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 8.03 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 3.87; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    4D Molecular Therapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$12.77

The share price is 2% above this estimate.

20%+ below
Near fair value
20%+ above
$12.99Price
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B1.8×1.4×2.3×$10.2850%
P/S12.0×19.0×4.8×$15.2650%
Fair value$12.77100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 1.4
  • Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$12.39M
Value traded per 1% price move
$3.47M

Downside

High risk

Typical loss in a bad month
31.4%
Volatility (annualized)
77%
Sharpe ratio, 1 year
0.30
Beta to the S&P 500 (5Y)
1.35

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2018 to 2025

Operating margin

-187.2%+229.0 pts over 5 years

Net margin

-164.4%+252.1 pts over 5 years

See a number that looks wrong?